Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3β-(2)-bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells

Clinical Cancer Research

Volumn 10, Issue 23, 2004, Pages 8018-8027

  Swamy, Narasimha ^a,e   Chen, Tai C ^a   Peleg, Sara ^b   Dhawan, Puneet ^c   Christakos, Sylvia ^c   Stewart, LaMonica V ^b   Weigel, Nancy L ^b   Mehta, Rajendra G ^d   Holick, Michael F ^a   Ray, Rahul ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF ILLINOIS   (United States)

^e BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CALCIFEDIOL 3BETA (2) BROMOACETATE; CALCIFEDIOL DERIVATIVE; CALCITRIOL 24 HYDROXYLASE; CALCITRIOL DERIVATIVE; CALCIUM; COLECALCIFEROL DERIVATIVE; COLECALCIFEROL RECEPTOR; PROTEIN GRIP 1; RETINOID X RECEPTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CALCIUM BLOOD LEVEL; CANCER CELL; CANCER INHIBITION; CELL GROWTH; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL STRAIN COS7; CONTROLLED STUDY; COVALENT BOND; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; GENE ACTIVITY; GENETIC TRANSFECTION; HORMONE RECEPTOR INTERACTION; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; KERATINOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; REPORTER GENE; TOXICITY TESTING;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; ANIMALS; APOPTOSIS; CALCITRIOL; CARRIER PROTEINS; CASPASES; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; CHLORAMPHENICOL O-ACETYLTRANSFERASE; COS CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; HUMANS; KERATINOCYTES; MALE; MICE; NEOPLASMS, HORMONE-DEPENDENT; NERVE TISSUE PROTEINS; PROMOTER REGIONS (GENETICS); PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, CALCITRIOL; RETINOID X RECEPTORS; THYMIDINE; TUMOR CELLS, CULTURED;

EID: 9744221197     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0881     Document Type: Article

References (37)

1. Eckhardt S. Recent progress in the development of anticancer agents. Curr Med Chem Anti-Canc Agents 2002;2:419-39.
2. Sweet FW, Murdock GL. Affinity labeling of hormone-specific proteins. Endocr Rev 1987;8:154-84.
3. Haussler MR, Whitfield GK, Haussler CA, et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 1998;13:325-49.
4. Jones G, Strugnell SA, DeLuca HF. Current understanding of the molecular actions of vitamin D. Physiol Rev 1998;78:1193-231.
5. Johnson CS, Herrhberger PA, Bernardi RJ, Meguire TF, Trump DL, Vitamin D receptor: a potential target for intervention. Urology 2002;60:123-30.
6. Bouillon R, Okamura WH, Norman AW, Structure-function relationships in the vitamin D endocrine system. Endocr Rev 1995;16:200-57.
7. Dalhoff K, Dancey J, Astrup L, et al. A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer 2003;89:252-7.
8. Evans TR, Colston KW, Lofts FJ, et al. A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer. Br J Cancer 2002;86:680-5.
9. El Abdaimi K, Dion N, Papavasiliou V, et al. The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Res 2000;60:4412-48.
10. Colston KW, Pirianov G, Bramm E, Hamberg KJ, Binderup L. Effects of Seocalcitol (EB1089) on nitrosomethyl urea-induced rat mammary tumors. Breast Cancer Res Treat 2003;80:303-11.
11. James SY, Mercer E, Brady M, Binderup L, Colston KW. EB1089, a synthetic analogue of vitamin D, induces apoptosis in breast cancer cells in vivo and in vitro. Br J Pharmacol 1998;125:953-62.
12. Swamy N, Addo J, Ray R. Development of an affinity-driven double cross-linker: isolation of a ligand-activated factor, associated with vitamin D receptor-mediated transcriptional machinery. Bioorg Med Chem Lett 2000;10:361-4.
13. Swamy N, Ray R. Affinity labeling of rat serum vitamin D binding protein. Arch Biochem Biophys 1996;333:139-44.
14. Rheinwald JG, Green H. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell 1975;6:331-15.
15. Malich G, Markovic B, Winder C. The sensitivity and specificity of the MTS tetrazolium assay for detecting the in vitro cytotoxicity of 20 chemicals using human cell lines. Toxicology 1997;124:179-92.
16. Campbell MJ, Koeffler HP. Toward therapeutic intervention of cancer by vitamin D compounds. J Natl Cancer Inst (Bethesda) 1997;89:82-5.
17. 3 displays strong antiproliferative and cytotoxic behavior in prostate cancer cells. J Cell Biochem 2003;89:909-16.
18. 3. Biochemistry 2000;39:12162-71.
19. 3. Arch Biochem Biophys 1999;370:34-44.
20. 3, vitamin D receptor, that is covalently modified by an affinity labeling reagent. Arch Biochem Biophys 1997;34:91-5.
21. 3 receptor. J Biol Chem 1996;271:2012-7.
22. 3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. J Steroid Biochem 1996;58:367-76.
23. Blutt SE, McDonnell TJ, Polek TC, Weigel NL. Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 2000;141:10-7.
24. 3. Endocrinology 1995;136:20-6.
25. 3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology 1999;140:2071-6.
26. 3 leads to the induced differentiation of the myelomonocytic cell line. Genes Dev 1996;10:142-53.
27. Narvaez CJ, Welsh J. Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells. J Biol Chem 2001;276:9101-7.
28. 3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 1998;139:1197-207.
29. Shi Y. Caspase activation: revisiting the induced proximity model. Cell 2004;117:855-8.
30. 3 in prostate cancer. Mol Cancer Ther 2002;1:667-77.
31. 3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells. Endocrinology 2003;144:50-32.
32. Whitlatch LW, Young MV, Schwartz GG, et al. 25-Hydroxyvitamin D-1-alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. J Steroid Biochem Mol Biol 2002;2002;81:135-40.
33. Liu YY, Nguyen C, Peleg S. Regulation of ligand-induced heterodimerization and coactivator interaction by the activation function-2 domain of the vitamin D receptor. Mol Endocrinol 2000;14:1776-8.
34. 3 selectively induces bone formation. Proc Natl Acad Sci USA 2002;99:13487-91.
35. 3 (Ro-26-9228). Mol Endocrinol 2004;18:874-87.
36. Hussain EA, Mehta RR, Ray R, Das Gupta TK, Mehta RG. Efficacy and mechanism of action of 1α-hydroxy2-ethyl-cholecalciferol (1α[OH]D5) in breast cancer prevention and therapy. Recent Results Cancer Res 2003;164:393-411.
37. 3 (Calcitriol) and EB 1089. Cancer Epidemol Biomark Prev 1999;8:241-8.